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Research, and American College of Cardiology Sudden death (SD) of young people because of a variety of complex, predominantly genetic/congenital cardiovascular diseases is a riveting, devastating event and a public health and policy issue of increasing concern (1-6). The reliable identification of such individuals at risk for SD has become a major focus of the cardiovascular community for a number of reasons, including the opportunity to reduce SD events through selective disqualification from sports (7) and the primary prevention of SD with the implantable cardioverter-defibrillator for some high-risk patients with genetic heart diseases (8) (9) (10) (11) (12) (13) (14) . In addition, those SDs caused by underlying and unsuspected genetic or congenital cardiovascular diseases that occur in young trained athletes are a highly visible issue and have become a concern in both the public arena and the physician community (15) (16) (17) .
Consequently, the desire to screen populations theoretically at risk for cardiovascular disease to reduce morbidity and mortality is understandable in principle, and few would empirically argue against the potential benefit of this practice for some individuals. However, a debate has emerged regarding whether the conditions responsible for these tragic events can be detected effectively in populations of various sizes by the available testing and examination techniques, and specifically, there is debate concerning which strategies are potentially the most reliable to separate those individuals with disease from those who are probably unaffected (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) .
Most of this dialogue concerning SD prevention has been limited to the screening of young populations of competitive athletes, and the available data specifically related to cardiovascular screening efficacy (on which we largely and unavoidably rely) overwhelmingly come from such populations exclusively composed of trained athletes. Periodically, this has become a polarized controversy and public health debate, triggering a large and growing body of literature, including clinical studies.
but notably also an array of recent editorials, opinion pieces, proclamations, and reviews on both sides of the question, often without the advantage of new primary data . Most of these come from Italian investigators (n ¼ 19) and others (n¼14), who suggest that the ECG is a reliable and economically feasible diagnostic test, some prematurely pronouncing a paradigm shift (49, 78) , whereas others appear contradictory (49, 85) ; other statements have come from an American Heart Association (AHA) science advisory (87) and a report from the National Institutes of Health (23) . Indeed, the issue of preparticipation athlete screening for cardiovascular disease has become the subject of discussion in a number of countries, including the United States,* Italy (4, 18, 31) , Israel (28, 29, 31, 92, 93) , Germany (94) , Sweden (95) , the United Kingdom (60, 96) , China (97) , the Netherlands (98), France (99) , Norway (58), Denmark (5,100), Japan (101, 102) , Switzerland (103) , and Spain (104) .
The present discussion defines cardiovascular screening as an initiative intended to prospectively identify or raise suspicion of previously unrecognized and largely genetic or congenital cardiovascular diseases known to cause sudden cardiac arrest and SD in young people (3, 105) . This has become a highly visible and vigorously debated topic, because the SD risk associated with intense physical activity (in the setting of potentially life-threatening but occult cardiovascular disease) potentially could be modified by withdrawal from a competitive athletic lifestyle (18) and could even be preventable in high-risk patients by prophylactic treatment interventions (e.g., implantable cardioverter-defibrillators) (8) (9) (10) (11) (12) (13) (14) . The writing group believes that it has achieved a comprehensive and balanced portrayal of the highly visible but complex topic of population screening for cardiovascular disease in young people.
NEW SCOPE OF THE DOCUMENT
Although reports on cardiovascular screening efficacy have predominantly involved populations of adolescents and young adults participating in competitive athletics, the context of the present discussion is intentionally (and necessarily) much more expansive. Therefore, it is underscored that the present report is not limited in scope to universal mass screening for athlete populations but importantly includes considerations for screening large, young, and truly general populations (school-aged, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] years old, of both sexes) with respect to relevant logistical, ethical, legal, and societal issues (e.g., in the United States or other countries or communities of various sizes, in schools, or in regional or military populations). In the United States, this potential screening population would comprise z60 million young people nationally, including as many as an estimated 10 million competitive athletes (7.5 million interscholastic athletes and 500,000 intercollegiate athletes) (2, 3, 25, 55, 106) .
The theoretical aspiration to screen the entire 12-to 25- year-old population of the United States for cardiovascular disease with ECGs would be an undertaking of enormous magnitude, with massive resource demands, in a population that may be at lower risk than one confined to athletes (107) .
Indeed, systematic cardiovascular screening (beyond periodic preventive health evaluation (5) in recreational athletes and the general adolescent and young adult populations) has not been recommended or pursued previously, and such evaluations typically have been reserved for patients with symptoms suspected to be of cardiovascular origin. On the other hand, the fact that screening has been limited to competitive athletes in the past does not in principle itself justify the future exclusion of youthful nonathletes from screening for lethal cardiovascular disease. Therefore, it appears only logical and fair that when relatively small athlete populations are targeted for screening, at least some consideration should be given to extending this screening to nonathletes in the same jurisdiction and venue.
Finally, this discussion does not specifically address the care provided to healthy individual subjects in an office practice. This represents a much different screening alternative within the U.S. healthcare system, which is restricted by the cost of such examinations generally not reimbursed by insurance carriers (in the absence of suspected disease).
SCREENING WITH THE ECG
The 12-lead ECG has been a widely used test to diagnose cardiovascular disease, particularly acute myocardial infarction, in clinic-and hospital-based practice for z70 Europe and the United States (5) . Notably, the discussion of such mass screening initiatives and models has come to be regarded as complex by virtue of 1) the low prevalence of cardiovascular diseases responsible for SD in the young population, 2) the low risk of SD among those with these diseases, 3) the large sizes of the populations proposed for screening, and 4) the imperfection of the 12-lead ECG as a diagnostic test in this venue.
Echocardiography, although not a primary subject of the present discussion, does harbor advantages for clinical diagnosis of certain conditions, such as hypertrophic cardiomyopathy (HCM) (108) . However, neither echocardiography nor cardiovascular magnetic resonance has been considered seriously as a primary cardiac imaging strategy or modality for large-scale universal preparticipation screening because of impracticality, cost, and interobserver variability (109) . Echocardiograms, nevertheless, are an important part of second-tier examinations that frequently occur when screening ECGs or other clinical findings are judged abnormal (2, 3, 17, 55, 109) .
Both AHA (3) and ESC (5) consensus panels have agreed previously that screening to detect cardiovascular abnormalities in asymptomatic young competitive athletes is justifiable in principle on ethical, legal, and medical grounds. Reliable exclusion of cardiovascular disease by such screening may provide a large measure of reassurance to this specific population of young people and their families. However, the U.S. and AHA position against national mandatory screening ECGs of athletes in the United States has periodically been the source of strong reaction and criticism from some investigators (16, 27, 39, 43, 62, 77, 110) . In addition, the question has arisen of whether such a mass screening program with ECGs is ethically defensible if confined to only 1 segment of the population when others may also be at risk.
BACKGROUND OF U.S. SCREENING PROGRAMS
Although rare, SDs in young people are nonetheless tragic, devastating events. Consequently, the detection of silent predominantly genetic/congenital cardiovascular conditions responsible for SD is an objective consistent with a benevolent and compassionate society. In the past, participants in competitive sports have been preferentially targeted for such screening programs, apparently because of their unique, physically active lifestyle (4) (5) (6) (7) 107) . Indeed, in the United States, there is a long-standing (>50 years) customary practice of systematic preparticipation screening required for participation in most organized youth and sanctioned high school, college, and professional sports, principally by use of history-taking and physical examination (20, 22, 111) . Of note, similar mass examination initiatives have not been advocated for the much larger general population of children, adolescents, and young adults who may not participate in organized sports activities, and therefore, there are virtually no data from such cohorts regarding the detection of cardiovascular disease.
In 1996 and again in 2007, the AHA provided consensus recommendations for such evaluations specifically in competitive athletes (3, 105, 112) component, places a high premium on excellence and achievement, and requires some form of systematic (and usually intense) training (7, 113) . Twelve elements (now 14) of the personal and family history and physical examination were recommended as part of a comprehensive medical questionnaire to be used as a guide to examiners conducting preparticipation examinations (Table 1) , although the precise penetrance of these guidelines into various levels of clinical practice is uncertain (114) . Other societies have also formulated useful guidelines for the preparticipation history and physical examination (115) .
In the United States, the preparticipation screening process has lacked a measure of standardization, including in the selection of examiners, who have traditionally included professionals from a variety of disciplines with different levels of training and expertise (e.g., physicians, nurse practitioners, physician assistants, and chiropractors in a minority of the states), often participating as volunteers (3, 20, 22) . Physicians responsible for screening are most often from the primary care and sports medicine disciplines but may also include a variety of other medical or surgical specialists (but rarely with specific cardiovascular training).
However, more recently, cardiologists have become more involved with the care of athletes, mostly at the elite level. This practice contrasts sharply with the Italian model (116) , in which screening is performed by a cadre of specially trained primary care-sports medicine physicians dedicated to examining all athletes in the national program, as well as being responsible for disqualification decisions (4, 5, 18) .
CARDIOVASCULAR CAUSES AND EPIDEMIOLOGY OF SD IN THE YOUNG
The causes of SD in the age group addressed here have been well documented, although based primarily on studies in the competitive athlete population, often in the form of large registries and forensic databases (1, 2, (4) (5) (6) (117) (118) (119) (120) (121) (122) . There is no evidence at present that the specific causes of SD differ significantly in nonathletes.
The causes of SD in trained U.S. athletes 12 to 35 years of age have been reported in a consistent fashion since 1980 (1, 2, 6, 117, (120) (121) (122) (123) . A heterogeneous variety of mostly congenital/genetic diseases (z20) are responsible for these events, with HCM (1-3,6,7,117,122,124-125a) being the single most common cause of SD, constituting approximately one third of cases (1, 2, 6, 117, 119, 125) .
Congenital coronary anomalies (most commonly those of wrong sinus origin) are responsible for 15% to 20%, with several other diseases each being responsible for z5% or less, including myocarditis, valvular heart disease (e.g., mitral valve prolapse, aortic stenosis), dilated cardiomyopathy, ruptured aortic aneurysm, premature atherosclerotic coronary artery disease, and arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D), as (4, 14, 31, 130, 131) . Atherosclerotic coronary artery disease is also relatively common in Veneto, whereas HCM (the most common cause of SD in U.S. registries) (1, 2, 6, 117, 122) is a rare cause of these deaths in the Italian (Veneto)
experience.
Long-standing screening efforts in athletes in the United States, Italy, and Israel have been predicated on the rationale that individuals engaged in competitive sports represent a special subset of the general population who are at significantly higher risk for SD than individuals of similar age who are not involved in such athletic activities and lifestyle (6, 26, 31, 107, 117) . Such an assertion has been used to justify screening initiatives that target only competitive athletes. However, although the premise that SD caused by underlying (and unsuspected) cardiovascular disease is more common with engagement in intense physical exertion is intuitive and supported by some data (6, 107) Figure) . Indeed, in a 10-year study of U.S. college athletes, Maron et al. (125) found suicide and drugs to be as frequently responsible for SD as cardiovascular disease. Although SD caused by cardiovascular disease in young people engaged in competitive sports is a significant public health concern, its relatively low incidence could limit the overall priority for universal primary prevention screening ( Figure) . In triathlon competition (which includes distance running up to the marathon distance), 1 study reported a higher SD rate of 1.5 per 100,000 participants, with 90% of the events occurring during the swimming segment (144) .
Professional Athletes
The relatively small number of participants in professional 
SCREENING EXPERIENCES IN GENERAL POPULATIONS OF NONATHLETES
The few available data estimating the incidence or prevalence of SD in young people in large general populations
(not confined to athletes) suggest that mortality rates generally exceed those reported for competitive athletes.
Specifically, out-of-hospital cardiac arrest incidence has been reported variously as 6.4 per 100,000 person-years Denmark there was no difference in the incidence of sudden death between noncompetitive and competitive athletes, both of which were significantly lower than in the general population (154a).
Military Personnel
Because engagement in the military is a highly physical enterprise, SD rates attributable to unsuspected cardiovascular disease are often compared with those in trained athletes (155, 156) . Sudden nontraumatic cardiac death among active duty military generally occurs at higher rates than in trained athletes, probably because intensive, prolonged exertion is performed under extreme environmental conditions, often by previously untrained individuals; rates are 6.7 per 100,000 person-years in men 
Sudden Infant Death Syndrome
The relation between sudden infant death syndrome (SIDS) and long-QT syndrome (LQTS) was first proposed by Although the available data suggest that neonatal LQTS can be detected by screening (162) , these studies have failed to demonstrate that lives are saved by this strategy.
School-Aged Children
Relatively few screening programs have focused on the 1-to 12-year-old age group. The 1973 Japanese School
Health Law mandated cardiovascular screening with modified ECG and history/physical examination for thousands of children in the first, seventh, and tenth grades (101, 102, 168) . However, few relevant diseaserelated data have emerged from this initiative given that a variety of generally minor cardiovascular abnormalities or arrhythmias without underlying organic heart disease were identified in only 2% to 3% of children. 
OTHER SCREENING INITIATIVES

SCREENING MEDICAL HISTORY AND PHYSICAL EXAMINATION
There is general agreement that conducting a comprehensive screening personal and family history and physical examination is usefulk; however, data supporting the efficacy of such a screening strategy alone are limited.
Available evidence shows that the personal/family history, as part of the preparticipation examination, is rela- or symptoms such as chest pain (common in adolescents and often difficult to interpret) should receive sufficient weight to warrant an expensive cardiovascular referral and evaluation (173) . This often becomes a dilemma for examiners, given that the vast majority of such individuals are likely to be unaffected, and the finding will be benign. Although the 12-lead ECG can be regarded as more sensitive than the history and physical (91, 98, 104, 172) , it is nevertheless associated with reduced specificity because of false-positive results (17, 24, 25, 55, 64, 65, 88, 91) . However, the acknowledged insensitivity of the history and physical examination screening cannot be considered a major justification for mass screening of general populations with ECGs.
Unfortunately, there is apparently a considerable lack of awareness (and compliance) regarding the use of history and physical examination questionnaires to guide the preparticipation screening examination (3, 20, 22, 114, 176, 177) . Indeed, certain standardized and comprehensive questionnaire forms developed specifically to assist primary healthcare providers in performing these examinations have been grossly underused, specifically the AHA recommendations (3, 105, 112, 114) and the Preparticipation Physical Evaluation monograph/ form, which is the work of several different societies (115, 176) .
It has been an important aspiration to enhance the quality of the history-taking and physical examination process (including the expertise of examiners) in accordance with the specific 14-point recommendations of the AHA (3,105) ( Table 1 ), given that many states have examination questionnaires judged inadequate to reliably raise suspicion of cardiovascular disease in high school studentathletes (20, 22) . In 1998, Glover and Maron (22) and changes in pattern in the ECGs in young patients (108, 119) . This is a potential source for false-negative diagnoses (15, 93, 185, 189, 190) .
Technical Factors
Similar to many tests, the ECG is subject to issues related to consistency, reproducibility, and interobserver vari- there are technical sources of potential nonbiological variability that limit the reliability of measurements, distort waveforms, reduce reproducibility, and blur the distinction of normal from abnormal tracings (191, 192) .
Among the most important of these is operator selection of inadequate bandwidth for the ECG (193) (194) (195) . In children and adolescents, inappropriate low-pass filtering (high-frequency cutoff <250 Hz) limits noise in the recorded signal but reduces the amplitude of R waves used to estimate ventricular mass (195) (196) (197) , whereas inappropriate high-pass filtering (low-frequency cutoff >0.05 Hz or its digital equivalent) limits baseline wandering but can introduce artifactual deviation of the J point and ST segment (198, 199) .
A major source of potential technical error is misplacement of the limb or precordial electrodes, not uncommonly including inadvertent lead reversals (200) (201) (202) (203) (204) (205) (206) , in which the V 1 and V 2 leads are placed in the second (rather than the fourth) intercostal space and the left precordial V 5 and V 6 leads are placed below the horizontal extensions of V 4 in the fifth intercostal space (205, 207) .
Precordial lead misplacement results in distorted precordial R-wave progression, thereby simulating anteroseptal infarction; magnifies otherwise small terminal R 0 deflections and elevates the ST segments in V 1 and V 2 ; and confuses standard criteria for diagnosis of ventricular hypertrophy (208) (209) (210) . Because day-to-day lead misplacement itself often varies, reproducibility of the precordial ECG is poor, and this variability can limit the ability to separate normal from abnormal tracings (192, 208) .
Another source of variability in assessment of the ECG involves standardization of interval durations, which have changed with newer technology (192, 211 There are also technical issues that explain variations in QT partition values, and reliance on computer-generated diagnostic interpretation of ECGs alone will fail to identify many family members at risk for LQTS (212) (213) (214) .
QT and other intervals were originally measured from 
Reliability of ECG Diagnostic Criteria
A major obstacle in screening is the overlap in measurements with the ECG between healthy subjects and those with prognostically important cardiac disorders, which may involve measurements of amplitudes, interval durations, and waveform shape. Furthermore, the spectrum of alterations in the ECG in healthy young athletes and nonathletes can overlap and in some cases (5% of elite athletes) (190, 219) Often ignored in this discussion is the importance of false-negative test results in the ECGs, which reflect low sensitivity (93, 97, 125, 127, 189, 190) . In the current environment, false-negative results can be expected in $10% It is evident and commonly accepted that no screening strategy can be considered absolute (i.e., 100%) in its ability to detect those cardiovascular diseases responsible for SD in young people. Indeed, a 26-year study of Minnesota athletes (with autopsy examinations) (127, 129) showed that only 40% Therefore, this strategy to reduce false-positive results could be regarded as an unfavorable tradeoff in screening.
Positive and Negative Predictive Values
The positive predictive value of a test is the proportion of true positive outcomes among all positive tests in a study population. The negative predictive value is the proportion of true negative outcomes among all negative tests (188) . Predictive value depends to a great extent on the incidence of the disease in the population, which is assessed by the test.
For screening tests such as the ECG, the positive predictive value for disease is less dependent on test sensitivity than on its specificity. The positive predictive value of a test (such as the ECG) with imperfect specificity is poor when the population prevalence of the disorder being tested is low, as is the case for all cardiovascular abnormalities associated with SD in young people. Even a test with nearly perfect specificity will have more falsepositive than true-positive responses when prevalence of disease in the population is <10% (187).
With a prevalence of disease <1%, and perhaps <0.1%
for even the most common channelopathies and inherited forms of cardiomyopathy (i.e., HCM), the positive predictive value of the ECG is small or trivial. When the prevalence of rare causes of adverse outcome in young people is as low as 0.1%, the negative predictive value of the ECG nevertheless remains high irrespective of test sensitivity. Indeed, the negative predictive value for extremely low-prevalence events is a questionable statistical concept, because nearly all subjects in the normal screening population will almost certainly remain free of adverse outcomes.
Impact of Age and Growth
Defining an abnormal ECG is particularly difficult in growing children and adolescents because of changes in heart rate, QRS axis, ventricular predominance, intraventricular conduction, and repolarization morphology. 
Race and Sex
It is becoming apparent that sex, race, and ethnicity are important determinants of pattern in the ECG (6, 117, (225) (226) (227) (238) (239) (240) (241) (242) . Notably, ethnic and racial differences are 
SCREENING ECGs AND CLINICAL OUTCOME/MORTALITY RATES
A distinctive body of literature has emerged from several countries describing preparticipation screening strategies, specifically assessing the impact of screening ECGs on mortality in athlete populations.## However, at present and importantly, there is no consensus from these data to support the principle that the addition of 12-lead
ECGs to history and physical screening actually reduces mortality.
The Italian (Veneto) Experience
The sole evidence that a mandatory screening strategy with a resting 12-lead ECG reduces SD mortality in young people comes from the study of competitive athletes in the Veneto The average annual mortality incidence before and af- 
COST, CHARGES, AND COST-EFFECTIVENESS
Although it is not possible to place a specific monetary value on a young life terminated suddenly and prematurely by underlying (and unsuspected) heart disease, cost is nevertheless an unavoidable concern when one deliberates the merits of large-scale screening programs.
Cost-efficacy data have potential value in healthcare policy decisions. All such cost-effectiveness studies must be regarded as highly theoretical estimates, because they are unavoidably based on numerous contestable assumptions. To place absolute cost into perspective, the $2 billion per year exceeds the annual budget of most major U.S. medical centers and is similar to that for the National Heart, Lung, and Blood Institute. Therefore, public health efforts targeting other prevalent problems in this age group that account for many more deaths annually, e.g., driving while intoxicated or distracted, drug use, or suicide, would likely be far more cost-effective. This discussion of cost and resource limitations is focused on the United States but in principle may also be relevant to other countries considering mass screening ECGs at this time.
INSIGHTS FROM PRIOR SCREENING STUDIES WITH ECGS
A literature search identified 17 published studies including 89,697 healthy subjects that reported the results of large screening initiatives with ECG, echocardiography, or both (as well as history and physical examination***; Table 2 ). Each of these studies was designed to detect a variety of largely genetic/congenital cardiovascular diseases, targeting predominantly adolescent and young adult participants in organized competitive sports ranging from high school to the professional level. These athletes were most commonly in basketball, football, and soccer. The majority of reports were from the United States (60%), but others came from Italy, the United Kingdom, Spain, Germany, and China; several were biracial. The athletes reported in these studies represent a heterogeneous group in terms of duration and intensity of training and level of performance, as well as age, sex, race, and other variables, but appear to generally be in accord with the 36th Bethesda Conference definition of a competitive athlete (7, 113) .
The percentage of athletes reported with abnormal findings on ECGs during screening initiatives varies widely from 2.5% in 1 study of high school athletes (229) to 35% in professional athletes (225) , with the average being z12%, greatly dependent on the precise criteria used to define abnormal patterns in the ECGs ( Table 2) . Notably, the vast majority (probably >90%) of abnormal ECGs in these populations represent false-positive test results.
The frequency of cardiac abnormalities was on average z5% for those detectable by history alone and z2.5% for those suspected on the basis of physical examination.
These screening studies reported a relatively low yield of highest-risk cardiac diseases. For example, among the nearly 90,000 athletes screened, there were only 6 definitive diagnoses of HCM (91, 94, 104, 255) , although 38
other athletes with increased septal thickness >13 mm were noted ( Table 2) . Explanations for the low frequency of HCM diagnoses are elusive, given that a number of independent surveys worldwide have identified HCM to occur in at least 1 in 500 of the general population (0.2%) (257, 258) . Nevertheless, it would appear that this discrepancy is very likely attributable to the not insignificant false-negative diagnostic testing rate for HCM using ECG, or history/physical examination. The Italian data from Veneto reported new cases of HCM detected by ECG and history/physical examination screening in 0.07% of 33,735 athletes over a 17-year period (18) .
Overall, the most commonly detected clinically reported diseases reported in these studies were bicuspid aortic valve, mitral valve prolapse, and Wolff-Parkinson-White syndrome, with LQTS less common. Few studies have described management strategies for those athletes with detected abnormalities, and the reported disqualification rate is low (0.2%-4%) (66, 225, 254) . No data are available regarding the effect that such disqualifications have on mortality rate. Maron et al. Assessment of the 12-Lead ECG as a Screening Test [266] , and lung [266, 267] n The 12-lead ECG does not qualify as a precise, validated, and suitable screening test known to reliably distinguish the affected from the nonaffected.
COMMUNITY-BASED INITIATIVES WITH NONINVASIVE TESTING IN THE UNITED STATES
n General agreement is lacking on the criteria for defining an abnormal ECG in screening such populations.
n Evidence is lacking from randomized or prospective controlled trials showing that screening ECGs are effective in reducing morbidity and mortality. (90, 279) . Thus, it is important to understand that as with those recommendations, the legal effect of the present 2014 screening guidelines is uncertain and will likely vary by jurisdiction. In some states, these guidelines may constitute some evidence of the medical standard of care for mass screening of large populations of young people.
In other states, compliance with these guidelines may establish a rebuttable presumption that a physician has in fact met the appropriate legal standard of care, or this may not even be admissible evidence concerning the issue. In most states, however, the legal consequences of failure to comply with AHA screening guidelines cannot be determined definitively at this time (281) .
Despite the lack of any specific legal precedent to minimize potential legal liability for medical malpractice, it is prudent for physicians to provide the minimum level of screening recommended by the present AHA guidelines 
Recommendations
The committee affirms that cardiovascular screening programs (independent of size, scope, or design) should be driven by sound scientific principles and policy and not by reaction to catastrophic events or political pressure from advocacy groups. In light of this acknowledgment and the data reviewed in the present document, the following recommendations for cardiovascular screening in young people aged 12 to 25 years are presented:
1. It is recommended that the AHA 14-point screening guidelines ( Table 1) 5. Consideration for large-scale, general population, and universal cardiovascular screening in the age group 12 to 25 years with history-taking and physical examination alone is not recommended (including on a national basis in the United States) (Class III, no evidence of benefit; Level of Evidence C).
FINAL INSIGHTS
The preponderance of evidence indicates that SD in young athletes (and probably nonathletes) in the age range of 12 to 25 years should be regarded as a low event rate occurrence. The writing group understands that additional data regarding the cost efficacy of screening initiatives and testing performance in large populations, as well as the prevalence/incidence of SD events, would be potentially helpful. However, to achieve a precise incidence of SD in youthful populations would require a national mandatory reporting process with a centralized database and dedicated resources, a program that will be difficult to establish and maintain. Furthermore, a ran- This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition. *Modest. †Significant.
